Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP

- Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticated financial institutions, family offices, and leading multinational corporations (strategic investors). PVP III LP's strategic investors include a who's who of market leaders around the world in their respective industries, including Pfizer Inc. (NYSE: PFE), Corning Incorporated (NYSE:GLW), W. L. Gore & Associates, Showa Denko K. K. (TYO:4004), Nissan Chemical Corporation (TYO:4021), Nagase & Co., Ltd. (TYO:8012), and LG Technology Ventures, which is the investment vehicle of LG Chem, Ltd. (KRX: 051910).

As the leading venture capital firm focused on Advanced Materials and Device investing, PVP has an established track record of strong returns and is known by entrepreneurs and corporations globally. PVP also has a reputation for forging deep partnerships with its strategic investors working closely with them on open innovation to identify attractive market opportunities. Building off the success of its first two funds, PVP III LP will continue to focus on investing in start-ups developing breakthrough Advanced Materials and Device innovations while expanding its presence globally.

Dr. John T. Chen , Managing General Partner of PVP, commented, "We are pleased by the strong interest in PVP III LP from new investors and continued support from our existing LPs and are happy to have closed the new fund despite the current global challenges."

Dr. Zachariah Jonasson , Managing General Partner of PVP added, "We are excited to be working with both the most innovative multinational corporations and entrepreneurs globally."

About Phoenix Venture Partners LLC

Phoenix Venture Partners LLC is a leading venture capital firm that invests in and partners with outstanding entrepreneurs to commercialize breakthrough Advanced Materials and Device innovations. PVP's team has an unparalleled track record of founding, building and investing in successful Advanced Materials start-ups across multiple industries. The firm's investment strategy is flexible and predicated on assisting entrepreneurs with customer and supply chain partnerships, business development, as well as with strategic and operational support. PVP collaborates with a select ecosystem of forward-looking global corporations on business development and open innovation interests. PVP is based in the Silicon Valley with a satellite office in Seattle , WA.  For additional information please visit our website at www.phoenix-vp.com or email us at information@phoenix-vp.com .

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/phoenix-venture-partners-llc-raises-3rd-fund-pvp-iii-lp-301214652.html

SOURCE Phoenix Venture Partners, LLC.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...

Interactive Chart

Latest Press Releases

Related News